

Putting NICE guidance into practice

Bladder cancer: risk classification in non-muscle-invasive bladder cancer

**Implementing the NICE guideline on
bladder cancer (NG2)**

Published: February 2015

This is a risk classification table for non-muscle-invasive bladder cancer. It accompanies [bladder cancer](#) (NICE guideline NG2).

Issue date: 2015

It is not NICE guidance.

Promoting equality

Implementation of the guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in the guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

National Institute for Health and Care Excellence

Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT; www.nice.org.uk

© National Institute for Health and Care Excellence, 2015. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

Risk classification in non-muscle-invasive bladder cancer

There is no widely accepted classification of risk in non-muscle-invasive bladder cancer. To make clear recommendations for management, the Guideline Development Group developed the consensus classification in the table below, based on the evidence reviewed and clinical opinion.

Risk categories in non-muscle-invasive bladder cancer

Low risk	Urothelial cancer with any of: <ul style="list-style-type: none">• solitary pTaG1 with a diameter of less than 3 cm• solitary pTaG2 (low grade) with a diameter of less than 3 cm• any papillary urothelial neoplasm of low malignant potential
Intermediate risk	Urothelial cancer that is not low risk or high risk, including: <ul style="list-style-type: none">• solitary pTaG1 with a diameter of more than 3 cm• multifocal pTaG1• solitary pTaG2 (low grade) with a diameter of more than 3 cm• multifocal pTaG2 (low grade)• pTaG2 (high grade)• any pTaG2 (grade not further specified)• any low-risk non-muscle-invasive bladder cancer recurring within 12 months of last tumour occurrence
High risk	Urothelial cancer with any of: <ul style="list-style-type: none">• pTaG3• pT1G2• pT1G3• pTis (Cis)• aggressive variants of urothelial carcinoma, for example micropapillary or nested variants